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(MMP) activity and superoxide production in apolipoprotein E-knockout mice (ApoE-KO
mice).
Methods and Results: Female apoE-KO mice and wild-type (WT) mice at 6 weeks of age
were exposed to hypoxia (10.0±0.5% oxigen) for 3 weeks. Following 4 groups (5 mice
each) were studied :(a) WT mice in normoxia, (b) WT mice under hypoxia, (c) apoE-KO
mice in normoxia, and (d) apoE-KO mice under hypoxia. Low-density lipoprotein (LDL),
total cholesterol (TC) and thiobarbituric acid-reactive substances (TBARS) increased in
apoE-KO mice. The MMP activity by zymography and vascular superoxide production
assessed by lucigenin chemiluminescence in aorta were increased both in apoE-KO
mice and WT mice under hypoxia.
Conclusion: The increase of oxidative stress in aorta and serum caused by hypoxia was
more prominent in atherogenic apoE-KO mice than WT mice in female.
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Background : High mobility group-1 (HMG-1) protein is an ubiquitous and abundant chro-
matin component with chemoattractant effects leading to neuronal and tumor cell migra-
tion. HMG-1 is also secreted by activated macrophages (MACs), acting as a mediator of
inflammation and endotoxic lethality (Wang H et al. Science, 285: 248, 1999). However,
HMG-1 expression under various pathophysiological conditions of vascular lesions, is still
unknown. We investigated the expression of HMG-1, particularly by smooth muscle cells
(SMCs) of human atherosclerotic and restenotic coronary arteries after balloon angio-
plasty (PTCA).
Methods: Specimens were obtained at the time of directional coronary atherectomy of 26
restenotic (2.5 to 4 months post-PTCA) and 15 primary lesions tissue samples. All speci-
mens were immunohistochemically stained with antibodies against HMG-1, MACs, C-
reactive protein (CRP), nuclear factor kappa B (NF-KB), plasminogen, matrix metallopro-
teinases (MMP-3 and MMP-9) and 3 types of SMC myosin heavy chains (SM1, SM2 and
SMemb).
Results: Intense HMG-1 immunoreactivity was observed in nuclei and/or cytoplasm of
lipid-laden foamy SMCs and MACs from the intima of atherosclerotic plaques. HMG-1
positive SMCs expressed both NF-KB and CRP immunoreactivities. Co-expression of
HMG-1 and plasminogen and/or MMPs was also observed in these SMCs by immun-
odouble staining. These immunohistochemical findings were clearly observed in poly-
morphic SMemb-positive SMCs from coronary restenotic neointima, but could not be
observed in atrophic and spindle-shaped SMCs from fibrous plaques with scanty cellular-
ity and normal medial SMCs.
Conclusions: HMG-1 is expressed by MACs and activated SMCs. Thus, it may play
important roles in progression and vulnerability of primary coronary atherosclerotic
lesions by enhancing inflammatory responses, and in induction of restenosis post-PTCA
by increasing SMC migration.
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1141-189 Limited Antiplatelet Effect of Aspirin and Clopidogrel in 
Patients With Stable Coronary Artery Disease: The 
Platelet Glycoprotein Ia/IIa and Glycoprotein IIb/IIIa 
Genetics and Female Sex
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Impaired antithrombotic effect of aspirin has been suggested to be a risk factor for coro-
nary events in stable coronary artery disease (CAD). In the current series, we have anal-
ysed functional platelet phenotypes in stable CAD patients using aspirin as well as
combined aspirin and clopidogrel. These phenotypes were related to patient characteris-
tics as well as platelet GPIa/IIa, GPIb-IX-V and GPIIb/IIIa genotype status.
We took samples from 101 patients with stable CAD on aspirin at baseline and again
after a 300mg loading dose of clopidogrel. The antiplatelet effect of the treatment was
studied in whole blood with PFA-100 and in platelet-rich plasma with turbidometric aggre-
gations. We used 170s. cut-off limit for epinephrine closure time (CT-CEPI) and aggrega-
tion slope >10%/min for arachidonic acid (AA) (1.5mmol/L) as predetermined cut-off
points to identify aspirin non-responders. Clopidogrel response was determined by per-
centual inhibition of ADP (5 µmol/L)-induced aggregation from the pre-clopidogrel value
by aggregometry.
7% (AA) to 22% (CT-CEPI) of patients were defined as poor aspirin responders. 41% of
these aspirin non-responders were GPIIIa A2/A1 heterozygotes as opposed to 17%
among aspirin responders (p=0.02) using the PFA cut-off values. In addition, 45% of poor
aspirin responders were women as opposed to 20% of aspirin responders (p=0.02) with
PFA. Genotype and sex were not associated with aspirin response defined by AA-
induced aggregation.
24% of patients were poor responders to clopidogrel (with the 10% cut-off). The mean
inhibition of ADP-induced aggregation in GPIIIa A2/A1 heterozygotes was 16% and in
GPIIIa A1/A1 22% (p=0.04). The mean inhibition was 33% in GPIa/IIa A1A1 homozy-
gotes as opposed to 21% in other GPIa/IIa genotypes (p=0.02).
We conclude that poor response to aspirin and clopidogrel is common among individuals
with angiographically proven severe CAD. Female sex and the common platelet GPIIb/
IIIa receptor A2 allele are associated with a poor response to aspirin and the GPIIIa A2
allele and the rare GPIa A1/A1 genotype associate with clopidogrel response.
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Background: Enoxaparin (E) is used to treat a wide range of thromboembolic disorders.
Therapeutic anti-Xa activity has been defined as 0.5 -1.0 IU/ml with increased hemor-
rhagic risk reported at anti-Xa activity >1.5 IU/ml. Current dosing recommendations (1
mg/kg subcutaneous every 12 hours) do not adjust for age, gender, or creatinine clear-
ance (CrCl) >30 ml/min. Accordingly, we sought to determine anti-Xa activity in a cohort
of elderly patients receiving E.
Methods: We identified 36 consecutive patients greater than 65 years old (12 male, 24
female)admitted to our institution and treated with E for various clinical indications. All
patients had CrCl > 30ml/min. Blood samples for peak Anti-Xa activity were obtained at
steady state.
Results: Subjects had a mean age of 79 + 6 years, mean weight of 81.3 + 17.4 kg, mean
serum creatinine of 1.0 + 0.3 mg/dl and mean CrCl of 46 + 11 ml/min.Fifty-nine percent of
patients were treated for acute coronary syndome, 22% for atrial fibrillation and 11% for
deep venous thrombosis/pulmonary embolism. The mean anti-Xa activity for these study
patients was 1.3 + 0.4 IU/ml. Anti-Xa activity was >1.0 IU/ml in 25/36 patients (69%) and
>1.5 IU/ml in 10/36 patients (28%). Analysis by gender revealed 18/24 (75%) of female
patients with anti-Xa activity >1.0 IU/ml and 8/24 (33%) with anti-Xa activity >1.5 IU/ml.
Values for male patients were 7/12 (58%) and 2/12 (17%) respectively.
Conclusion: Current E dosing recommendations lead to supratherapeutic anti-Xa activ-
ity in a high percentage of elderly patients. Twenty-eight percent of elderly patients dem-
onstrate Anti-Xa activity >1.5 IU/ml. Elderly female patients are more likely to exhibit
elevated anti-Xa activity.
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Background: Contrast Induced Nephropathy (CIN) is a well known complication of coro-
nary angiography and angioplasty in patients with renal insufficiency. Prophylactic use of
Acetylcysteine in such patients has been reported to ameliorate CIN in multiple small
studies. The purpose of this report is to evaluate the cumulative evidence from reported
